Alzheimer’s disease (AD): risk factors
Evidence-based neurology checklist on alzheimer’s disease (ad): risk factors: Non-modifiable risk factors Age Fewer years of education Apolipoprotein E epsilon4 (APOE4) allele GGA3 gene deletion or variants Lifestyle risk factors Medical risk factors Metabolic risk factors Drug-related risk…
Non-modifiable risk factors
- Age
- Fewer years of education
- Apolipoprotein E epsilon4 (APOE4) allele
- GGA3 gene deletion or variants
Lifestyle risk factors
Medical risk factors
Metabolic risk factors
Drug-related risk factors
Proposed microbial risk factors
Iatrogenic Alzheimer’s disease
Risk factors for accelerated cognitive decline
Unlikely risk factors
References
- Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10:819-828.
- Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. JNNP 2015; 86:1299-1306.
- Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian study of health and aging. Am J Epidemiol 2002; 156:445-453.
- Lomoio S, Willen R, Kim W, Ho KZ, et al. Gga3 deletion and a GGA3 rare variant associated with late onset Alzheimer's disease trigger BACE1 accumulation in axonal swellings. Sci Transl Med 2020; 12:eaba1871.
- Pase MP, Himali JJ, Beiser AS, et al. Sugar- and artificially sweetened beverages and the risks of incident stroke and dementia: a prospective cohort study. Stroke 2017; 48:1139-1146.
- And 38 more. Subscribe to see the full list
Related checklists
- Alzheimer’s disease (AD): protective factors
- Alzheimer’s disease (AD): clinical features
- Alzheimer's Disease (AD) v frontotemporal dementia (FTD)
- Alzheimer’s disease (AD): investigations
- Alzheimer’s disease (AD): emerging investigations
- Alzheimer’s disease (AD): preventative measures
- Alzheimer’s disease (AD): non-drug management
- Alzheimer’s disease (AD): conventional drug treatments
- Alzheimer’s disease (AD): lecanemab treatment
- Alzheimer’s disease (AD): investigational treatments
- Alzheimer’s disease: driving and safety issues